Treatment of refractory crohn's disease and pyoderma gangrenosum with a combination regimen of rifaximin, gentamicin and metronidazole

Neil D. Goldberg, Aravinda Vadlamudi, Nicole Parrish

Research output: Contribution to journalArticlepeer-review

Abstract

The etiology of Crohn's disease (CD) remains controversial. It is hypothesized that CD is the result of an abnormal immune response to the gut flora in genetically susceptible hosts. However, an infectious etiology has not been completely ruled out. Antibiotics have been utilized with some success to modify the course of the disease. Here, we report a patient with CD and pyoderma gangrenosum refractory to standard therapy, including biologics, who achieved remission with a combination of rifaximin, gentamicin and metronidazole.

Original languageEnglish (US)
Pages (from-to)25-28
Number of pages4
JournalCase Reports in Gastroenterology
Volume9
Issue number1
DOIs
StatePublished - May 22 2015

Keywords

  • Combination therapy
  • Crohn's disease
  • Pyoderma gangrenosum

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Treatment of refractory crohn's disease and pyoderma gangrenosum with a combination regimen of rifaximin, gentamicin and metronidazole'. Together they form a unique fingerprint.

Cite this